Alembic Pharmaceuticals’ Board of Directors approved the unaudited financial results for the quarter and half-year ended September 30, 2025. Revenue from operations reached ₹1,910.15 crore for the quarter. The Board also approved the consolidated statement of assets and liabilities and cash flow statements for the specified period. The meeting concluded at 2:25 p.m. on November 4, 2025.
Financial Performance Highlights
Alembic Pharmaceuticals announced its unaudited financial results for Q2 2025, showcasing a revenue from operations of ₹1,910.15 crore. The results, approved by the Board of Directors, reflect the company’s performance for the quarter and half-year ending September 30, 2025.
Key Financial Details
The key highlights from the consolidated unaudited financial results include:
- Revenue from operations: ₹1,910.15 crore
- Total Income: ₹1,917.06 crore
- Profit before tax: ₹223.72 crore
- Profit for the period: ₹184.71 crore
Balance Sheet Overview
The consolidated statement of assets and liabilities indicates total assets of ₹8,396.93 crore as of September 30, 2025, compared to ₹7,772.94 crore as of March 31, 2025.
Cash Flow Statement Summary
The consolidated cash flow statement provides an overview of the company’s cash inflows and outflows. The net cash inflow from operating activities is reported as ₹402.92 crore for the half-year ended September 30, 2025.
Standalone Financial Results
In addition to the consolidated results, Alembic Pharmaceuticals also released standalone unaudited financial results. Key figures include:
- Revenue from operations: ₹1,796.24 crore
- Profit before tax: ₹216.35 crore
- Total Comprehensive Income for the period: ₹173.44 crore
Auditor’s Review
The statutory auditors have reviewed the results, with their report remaining unqualified. This provides assurance regarding the reliability and accuracy of the financial information presented.
Operational Updates
Alembic Pharmaceuticals is primarily engaged in the pharmaceuticals business. On July 2, 2025, Alembic Pharmaceuticals Inc., a U.S.-based subsidiary, completed the acquisition of a UK-based entity engaged in research and development activities for ₹221.97 crore. The insurance claim related to the Sikkim unit flash floods was fully settled, resulting in a net income of ₹12.87 crore recognized under Exceptional Items.
Source: BSE